KR
Keros Therapeutics, Inc.
KROS · NASDAQ
$11.48 +1.50% (+$0.17)
1M +6.49%
Market Cap $367.3M
P/E Ratio -
Div. Yield -
ROE 21.40%
Bulios Fair Price
$14.52
26.5% upside
Current Price
$11.48
Undervalued Fair Value Overvalued
According to Bulios Fair Price, KROS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
50 /100
Fair P/B 1.40x
P/S 24.47x
EV/EBITDA N/A
Growth
40 /100
Stable Book val. growth 3.00%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 553.88%
Op. margin 675.82%
FCF margin 322.95%
Quality
1 /100
Poor ROE 21.40%
ROA 28.91%
Asset turnover 0.05x
Debt
100 /100
Low Current ratio 21.96x
Debt/Equity 0.06x
Net debt/EBITDA N/A
Stability
35 /100
Moderate EPS volatility 91.65%
Profitable years 1
Beta 1.02x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about KROS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jasbir S. Seehra
Employees
92
Headquarters
Lexington
Upcoming events
04 NOV
Earnings
Upcoming earnings report